Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 172

1.

Endothelial dysfunction, increased inflammation, and activated coagulation in HIV-infected patients improve after initiation of highly active antiretroviral therapy.

Arildsen H, Sørensen KE, Ingerslev JM, Østergaard LJ, Laursen AL.

HIV Med. 2013 Jan;14(1):1-9. doi: 10.1111/j.1468-1293.2012.01027.x.

2.

[HIV infection, antiretroviral therapy, and endothelium].

Hürlimann D, Weber R, Enseleit F, Lüscher TF.

Herz. 2005 Sep;30(6):472-80. Review. German.

PMID:
16170677
3.

HIV type 1 infection, and not short-term HAART, induces endothelial dysfunction.

Francisci D, Giannini S, Baldelli F, Leone M, Belfiori B, Guglielmini G, Malincarne L, Gresele P.

AIDS. 2009 Mar 13;23(5):589-96. doi: 10.1097/QAD.0b013e328325a87c.

PMID:
19177019
4.

Reduction in circulating markers of endothelial dysfunction in HIV-infected patients during antiretroviral therapy.

Kristoffersen US, Kofoed K, Kronborg G, Giger AK, Kjaer A, Lebech AM.

HIV Med. 2009 Feb;10(2):79-87. doi: 10.1111/j.1468-1293.2008.00661.x. Erratum in: HIV Med. 2010 Jan;11(1):94.

5.

Soluble markers of inflammation are associated with Framingham scores in HIV-infected patients on suppressive antiretroviral therapy.

Guzmán-Fulgencio M, Medrano J, Rallón N, Echeverria-Urabayen A, Miguel Benito J, Restrepo C, García-Álvarez M, Vispo E, San Roman J, Sánchez-Piedra C, Soriano V, Resino S.

J Infect. 2011 Nov;63(5):382-90. doi: 10.1016/j.jinf.2011.08.006.

PMID:
21855573
6.
7.

Endothelial function in HIV-infected patients with low or mild cardiovascular risk.

Blanco JJ, García IS, Cerezo JG, de Rivera JM, Anaya PM, Raya PG, García JG, López JR, Hernández FJ, Rodríguez JJ.

J Antimicrob Chemother. 2006 Jul;58(1):133-9.

PMID:
16702174
8.

Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients.

Masiá M, Padilla S, Bernal E, Almenar MV, Molina J, Hernández I, Graells ML, Gutiérrez F.

Clin Ther. 2007 Jul;29(7):1448-55.

PMID:
17825696
10.

Cross-sectional study of endothelial function in HIV-infected patients in Brazil.

Andrade AC, Ladeia AM, Netto EM, Mascarenhas A, Cotter B, Benson CA, Badaró R.

AIDS Res Hum Retroviruses. 2008 Jan;24(1):27-33. doi: 10.1089/aid.2006.0281.

PMID:
18275345
11.

Endothelial markers and HIV infection in the era of highly active antiretroviral treatment.

de Larrañaga GF, Bocassi AR, Puga LM, Alonso BS, Benetucci JA.

Thromb Res. 2003 May 1;110(2-3):93-8.

PMID:
12893023
12.

Changes in biomarkers of cardiovascular risk after a switch to abacavir in HIV-1-infected individuals receiving combination antiretroviral therapy.

Kristoffersen US, Kofoed K, Kronborg G, Benfield T, Kjaer A, Lebech AM.

HIV Med. 2009 Nov;10(10):627-33.

PMID:
19891054
14.

Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.

Friis-Møller N, Weber R, Reiss P, Thiébaut R, Kirk O, d'Arminio Monforte A, Pradier C, Morfeldt L, Mateu S, Law M, El-Sadr W, De Wit S, Sabin CA, Phillips AN, Lundgren JD; DAD study group..

AIDS. 2003 May 23;17(8):1179-93.

PMID:
12819520
15.

Impact of NNRTI compared to PI-based highly active antiretroviral therapy on CCR5 receptor expression, beta-chemokines and IL-16 secretion in HIV-1 infection.

Burton CT, Hardy GA, Sullivan AK, Nelson MR, Gazzard B, Gotch FM, Imami N.

Clin Exp Immunol. 2002 Nov;130(2):286-92.

16.

Effect of atazanavir versus other protease inhibitor-containing antiretroviral therapy on endothelial function in HIV-infected persons: randomised controlled trial.

Flammer AJ, Vo NT, Ledergerber B, Hermann F, Gämperli A, Huttner A, Evison J, Baumgartner I, Cavassini M, Hayoz D, Quitzau K, Hersberger M, Sudano I, Ruschitzka F, Lüscher TF, Noll G, Weber R.

Heart. 2009 Mar;95(5):385-90. doi: 10.1136/hrt.2007.137646.

PMID:
18653575
17.

Endothelial function in HIV-infected patients receiving protease inhibitor therapy: does immune competence affect cardiovascular risk?

Nolan D, Watts GF, Herrmann SE, French MA, John M, Mallal S.

QJM. 2003 Nov;96(11):825-32.

PMID:
14566037
18.

Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1.

Wolf K, Tsakiris DA, Weber R, Erb P, Battegay M; Swiss HIV Cohort Study..

J Infect Dis. 2002 Feb 15;185(4):456-62.

PMID:
11865397
19.

Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes.

Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G.

Ann Intern Med. 2007 Apr 17;146(8):564-73.

PMID:
17438315
20.

Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières.

Pujades-Rodríguez M, O'Brien D, Humblet P, Calmy A.

AIDS. 2008 Jul 11;22(11):1305-12. doi: 10.1097/QAD.0b013e3282fa75b9.

PMID:
18580610

Supplemental Content

Support Center